Mutations analysis of BRCA1 gene in patients with breast cancer in South Khorasan province, East Iran

Ghazaleh Khalili-Tanha1, Ahmadreza Sebzari2, Mitra Moodi3, Fatemeh Hajipoor4, Mohsen Naseri*1

Received: 1 Sep 2018 Published: 2 Oct 2019

Abstract

Background: Breast cancer (BC) is well-known as the most common malignancy and the first leading cause of cancer-related death among women worldwide. Evidence suggests that familial history and age are important risk factors for the development of this disease in Iran. Mutations in BRCA1 and BRCA2 genes are the cause of 5 to 10% of hereditary BC. Recent studies demonstrated that mutations in BRCA1 were observed in high-risk women with family histories of BC. However, to date, the mutations have not been elucidated in BC patients from east of Iran. The purpose of this study was to analyze BRCA1 mutations in BC patient from South Khorasan Province.

Methods: In the present study, 88 BC patients (11 positive family history) were screened for mutations in BRCA1. The analysis of BRCA1 was carried out by SSCP (single-strand conformation polymorphism) for shorter exons and direct sequencing in the case of longer ones.

Results: Twenty-eight of the patients (31.8%) had a synonymous mutation (c.4308T>C) in exon 13. A missense mutation (c.4837A>G) was presented in exon 16 with a frequency of 56.8 %. In exon 11 three missense mutations were observed, and the frequency rate for c.3113A>G was 32.5%, for c.3119G>A was 5%, and the highest frequency belonged to c.3548A>G with 72.4% in familial BC and 45.4% in the non-familial group.

Conclusion: In our study, five mutations were found, but none of the founder mutations were identified in this population. Two missense mutations in exon 16 (56.8%) and in exon 11 (65%) had the highest frequency in South Khorasan Province.

Keywords: Breast Neoplasms, BRCA1 Gene, Single-Stranded Conformational Polymorphism (SSCP)

Conflicts of Interest: None declared
Funding: Birjand University of Medical Sciences

*This work has been published under CC BY-NC-SA 1.0 license.

Copyright © Iran University of Medical Sciences


Introduction

Breast cancer is considered as the most common malignancy as well as the second leading cause of mortality from cancer in women (1). The results of epidemiological studies show while the incidence and mortality rate of breast cancer has slightly decreased or stabilized in some developed countries like the US, the global incidence and mortality is increasing (2). There are many risk factors have been identified for breast cancer, among which age, gender (female), family history of breast cancer, geographic factors, race and ethnicity, reproductive history, and exposure to ionizing radiation are the most important and mentioned in lots of evidence (3).

Genetic factors play a decisive role in some cases of breast cancer. Cancer-causing genes categorized into three main types, including cellular proliferation inhibitors (tumor suppressors), proliferation activators (oncogenes),

What this article adds:
The present study screening BRCA1 mutation in the east of Iran for the first time was shown that the observed mutations have no correlation with breast cancer, therefore are known as polymorphism.
**BRCA1** gene mutations in breast cancer

and those participating in DNA repair (4). It has been estimated that about 5-10 percent of breast cancer patients have inherited susceptibility genes. The familial tendency to develop breast and ovarian cancer is called “hereditary breast-ovarian cancer syndrome”. A number of genes are associated with this syndrome; the best known is **BRCA** mutations. **BRCA1** and **BRCA2** are two DNA repair genes in which hundreds of mutations have been reported. **BRCA** mutations are associated with a significantly increased risk of breast cancer (5). Women inheriting **BRCA1** or **BRCA2** mutations experience 50-80% or 50% lifetime risk of breast cancer development, respectively (6). In patients with positive family history, screening of inherited gene mutations have been strongly recommended to determine a person’s risk of acquiring the specific type of cancer. As mentioned before, **BRCA1** and **BRCA2** exhibited more than 2000 allelic mutations, most of which are deletions or nonsense or frameshift mutations. Thus, finding and characterizing frequent mutation in each population is required (7).

Despite little genetic studies regarding **BRCA** mutations among breast cancer patients in Iran, to date, to the best of our knowledge, there is no clear information concerning the mutations of **BRCA1** in the eastern part of Iran. Therefore, the aim of the present study was to determine the **BRCA1** alterations in 88 diagnosed breast cancer women from the eastern part of Iran (South Khorasan province).

**Methods Subjects**

A total of 88 women diagnosed with breast cancer admitting to chemotherapy center of Birjand University of Medical Sciences (BUMS) from March 2016 to March 2017 were enrolled in the study. The study was approved by the Ethics Committee of Birjand University of Medical Sciences and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Moreover, during the first visit, all patients provided written informed consent to participate in the present study. All patients were interviewed by trained interviewers (Oncologists), and their baseline demographics were recorded from their clinical charts. Furthermore, 5 ml peripheral blood sample was collected from patients and stored at -20°C until use.

**Extraction of the genomic**

Blood samples were collected in EDTA-containing tubes, and genomic DNA was extracted from blood lymphocytes by using proteinase K/SDS digestion and salting-out extraction method (8). After measuring the DNA concentration and its purity by Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE), the genomic DNA was diluted to a final concentration of 50 ng/μl in dH2O and stored at 4°C until subsequent analysis. These DNA samples were stored at -70°C in the DNA bank of BUMS.

**PCR amplification of BRCA1 gene**

Primers specific to exon 2, 6, 13, 16, 20, 24 and partial of 11, were designed by using Primer 3 online software and databases such as NCBI and UCSC (Table 1). PCR amplification was performed in a 35μl reaction containing 50 ng genomic DNA, 3.5 μl 10X buffer, 1.4 μl MgCl2 (50mM), 0.3 mM each forward and reverse primers (10PM), 0.7 μlNTPs (10mM), 2.5 U Taq DNA polymerase (10 u/μl) and 26 μl of deionized H2O.

PCR was performed with an Eppendorf (Mastercycler, Westbury, NY). The amplification conditions consisted of an initial denaturalization for 4 min at 94°C; 35 cycles of 30 sec at 94°C and 30 sec at the annealing temperature of each pair of primers; 30 sec for elongation at 72°C; and a final extension step of 10 min at 72°C. The samples were maintained at 4°C until removal from the thermocycler. The presence of the PCR product was visualized by electrophoresis at 1.5% agarose gel.

**SSCP analysis and Staining**

Non-radioactive SSCP was performed as follows: a 5 μl volume of PCR product was denatured in 5 μl of formamide loading buffer (0.5 M EDTA, 95% formamide and 0.05% bromophenol blue), at 95°C for 10 min. In order to allow the fragments of ssDNA to fold into three-dimensional structures as a result of intrastrand base pairing, the product immediately placed on ice. Denatured samples were loaded onto 10% acrylamide gel electrophoresed at a constant 120 V at 4°C for 20 hours then the gel was stained with silver nitrate and revealed with sodium carbonate.

**Table 1. BRCA1** gene primer nucleotide sequences

<table>
<thead>
<tr>
<th>Exon no.</th>
<th>Nucleotide sequence</th>
<th>Annealing temperature (°C)</th>
<th>Amplified fragment length (bp)</th>
<th>Technique</th>
</tr>
</thead>
</table>
| 2        | F: GACGTTGTCAATTTAGTTCATTTGG  
R: GGTCAATTCTGTTCATTTGC  
F: GCGCTTATAAGTGTATGTGATG  
R: CCTACAGAGAAATATTGTCGTCGTC  
F: ATCACGTGAGGGCTTTGCTGT  
R: GGGAGACTTTCATCTCCTCCTC  
F: AATGGAAGGATCTTCTAAAGTATA  
R: AGTTGGAGGCTAGTTCCTTAC  
F: AATCTCTTACAGAGAGCAGAAGAC  
R: AAAACTCTTTCCAGAATGTTGT  
F: ATGTTGGAGCTAGGTCCTTAC  
R: GGGATACGCTCAGTCAATG  
F: ATGACGTGTTCTGCTGCAC  
R: AGTCTCTACCAAGGAGAAGGGG  
F: ATGACTTGACTAACATTTGTCGTC  
R: GTAAGCAGACAGTAAAGAGGA | 56  
314  
52  
311  
900  
320  
459  
449  
258  
279 | | SSCP-PCR  
SSCP-PCR  
SSCP-PCR  
DS  
SSCP-PCR  
SSCP-PCR  
SSCP-PCR  
SSCP-PCR  
SSCP-PCR  
SSCP-PCR |

SSCP=Single-strand conformation polymorphism, DS=Direct sequencing
Sequencing of the polymorphism SSCP products

The PCR products which had different pattern comparison with a healthy wild positive control pattern sent for sequencing determination (Biotech Company Kowsar, Iran, Tehran).

Statistical Methods

The genotype and allele frequency of BRCA1 were tested for Hardy-Weinberg equilibrium (HWE) using PowerMarker V3.25. The relationship between family history and clinicopathological characteristics were tested using Fisher’s exact test. Fisher’s exact test was selected for statistical analyses due to the scarcity of mutations. All data were analyzed in SPSS statistical software version 22 and P<0.05 was considered as statistical significance.

Results

In this cross-sectional study, a total of 88 DNA samples were collected from breast cancer diagnosed females, with or without a family history. The average age of patients was 46.28±9.85 years, 27 patients had early breast cancer (younger than 40 years of age), and two of them were affected by bilateral breast cancer. Although family history plays an important role in breast cancer, only 12.5% of patients had a positive history. Results of pathologic information were showed that most of the patients (81.4%) were affected with ductal carcinoma, and 98% of tumors were unilateral, including 60% right-sided tumors. The analysis did not reveal any significant differences between family history and clinicopathological characteristics such as age, menopause, smoking, type, and stage of cancer (Table 2).

88 patients were analyzed for BRCA1 gene mutations in exons 2, 6, 13, 20, and 24. Furthermore, a partial region of exon 11 (900 bp) was evaluated in 40 patients selected according to family history and early breast cancer (under 40 years old). These exons were selected based on several previous studies. These regions are considered as hotspots in the Iranian population (8). Following extraction of the DNA as previously described, mutations were detected by the SSCP technique, silver nitrate staining, and DNA sequencing (Fig. 1).

No mutations were observed in exon 2, 6, 20 and 24, but these have been identified five variants in this cohort: one synonymous mutation in exon 13 (c. 3113A>G), four of which were missense, three of them were in exon 11 (c. 3113A>G, c.3119G>A, c.3548A>G), and one of them was in exon 16 (c. 4837A>G). The mutations and allele frequencies are summarized in Tables 3 and 4.

Discussion

To the best of our knowledge, this is the first genetic study has been performed to evaluate BRCA1 mutations among BC patients in the South Khorasan (East of Iran). Accordingly, 88 breast cancer diagnosed women with positive family history (n=11) or those without such a history (n=77) were evaluated to determine BRCA1 mutations.

In the present study, the average age of cases was 48.2 years. A number of epidemiological studies have found that the average age of the patients in different parts of Iran is about 10-15 years lower than the western countries.

Table 2. Demographic and clinicopathological characteristics of patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>FBC</th>
<th>NFBC</th>
<th>Total</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age groups (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40</td>
<td>1(9.1)</td>
<td>27(36)</td>
<td>28(32.6)</td>
<td>0.69</td>
</tr>
<tr>
<td>&gt;40</td>
<td>10(90.9)</td>
<td>48(64)</td>
<td>58(67.4)</td>
<td></td>
</tr>
<tr>
<td>Menopause</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>8(72.7)</td>
<td>37(49.3)</td>
<td>45(52.9)</td>
<td>0.20</td>
</tr>
<tr>
<td>Negative</td>
<td>3(27.3)</td>
<td>38(50.7)</td>
<td>41(47.1)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>1(9.1)</td>
<td>8(10.7)</td>
<td>9(10.5)</td>
<td>0.67</td>
</tr>
<tr>
<td>Negative</td>
<td>10(90.9)</td>
<td>67(89.3)</td>
<td>77(89.5)</td>
<td></td>
</tr>
<tr>
<td>Cancer type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ductal carcinoma</td>
<td>7(100)</td>
<td>43(86)</td>
<td>50(88.1)</td>
<td>0.60</td>
</tr>
<tr>
<td>Lobular carcinoma</td>
<td>0(0)</td>
<td>7(14)</td>
<td>7(11.9)</td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>0(0)</td>
<td>5(10.6)</td>
<td>5(9.3)</td>
<td>0.46</td>
</tr>
<tr>
<td>II</td>
<td>4(66.7)</td>
<td>36(76.6)</td>
<td>40(75.9)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>2(33.3)</td>
<td>6(12.8)</td>
<td>8(14.8)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>0(0)</td>
<td>7(14)</td>
<td>7(11.9)</td>
<td>0.28</td>
</tr>
<tr>
<td>II</td>
<td>4(57.1)</td>
<td>26(52)</td>
<td>30(50.8)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>3(42.9)</td>
<td>14(28)</td>
<td>17(30.5)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>0(0)</td>
<td>3(6)</td>
<td>3(6.8)</td>
<td></td>
</tr>
<tr>
<td>Estrogen receptors(ER)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>6(85.7)</td>
<td>34(60.7)</td>
<td>40(64.6)</td>
<td>0.39</td>
</tr>
<tr>
<td>Negative</td>
<td>1(14.3)</td>
<td>22(39.3)</td>
<td>23(35.4)</td>
<td></td>
</tr>
<tr>
<td>Progesterone receptors (PR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>3(42.9)</td>
<td>31(58.5)</td>
<td>34(56.5)</td>
<td>0.72</td>
</tr>
<tr>
<td>Negative</td>
<td>4(57.1)</td>
<td>22(41.5)</td>
<td>26(43.5)</td>
<td></td>
</tr>
<tr>
<td>HRE2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>3(42.9)</td>
<td>14(25.5)</td>
<td>17(26.6)</td>
<td>0.41</td>
</tr>
<tr>
<td>Negative</td>
<td>4(57.1)</td>
<td>41(74.5)</td>
<td>45(73.4)</td>
<td></td>
</tr>
</tbody>
</table>

FBC, Familial Breast Cancer; NFBC, Non-Familial Breast cancer.
**BRCA1** gene mutations in breast cancer

Fig. 1. Single-strand conformation polymorphism (SSCP) assay for a mutation in BRCA1, which were confirmed by direct sequencing. (a): Silver-stained gel showing bands of exon 13, lanes 2 and 3 wild-type sequence, lane 1 heterozygous and lane 4 homozygous variant (c.4308T>C). (b): Silver-stained gel showing bands of exon 16, lane 2 wild-type, lane 1, 3 and 4 heterozygous polymorphism (c. 4837A>G).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Exon</th>
<th>Sequence variant</th>
<th>AA change</th>
<th>RefSNP</th>
<th>Mutation type</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1</td>
<td>13</td>
<td>c.4308T&gt;C</td>
<td>Ser1436Ser</td>
<td>rs1060915</td>
<td>Synonymous</td>
<td>4 (36%)</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>c.4837A&gt;G</td>
<td>Ser1613Gly</td>
<td>rs1799966</td>
<td>Missense</td>
<td>7 (63.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>43 (55.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50 (56.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28(31.8)</td>
</tr>
</tbody>
</table>

Table 4. Genotype and allele frequency of five distinct polymorphic sites of **BRCA1** gene in breast cancer patients

<table>
<thead>
<tr>
<th>Polymorphic sites</th>
<th>Genotype frequencies (%)</th>
<th>Allele frequencies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>W/W</td>
<td>W/V</td>
</tr>
<tr>
<td>Ex-11 (Glu1038Gly)</td>
<td>27 (67.5)</td>
<td>13 (32.5)</td>
</tr>
<tr>
<td>Ex-11 (Ser1040Arg)</td>
<td>38 (95)</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Ex-11 (Lys1183Arg)</td>
<td>24 (60)</td>
<td>12 (29.5)</td>
</tr>
<tr>
<td>Ex-11 (Ser1436Ser)</td>
<td>60 (62.2)</td>
<td>16 (18.2)</td>
</tr>
<tr>
<td>Ex-16 (Ser1613Gly)</td>
<td>38 (43.2)</td>
<td>56 (62.8)</td>
</tr>
</tbody>
</table>

W/W, Wild type; W/V, Homozygote, mutant; V/V, Heterozygote; p, Normal allele; q, mutant allele.

Similar to our result, Heydari et al. have reported that the mean age of BC patient in the south of Iran was 46.3 years (9). Moreover, in a systematic review and meta-analysis study in which 52 studies with 332999 BC cases were included, the average age of Iranian patients was 48.59 years (10).

Mutations in exons 2, 6, 13, 16, 20, and 24 were screened by SSCP technique, and a 900bp fragment of exon 11 was analyzed by using direct sequencing. No mutation was observed in exon 2, 6, 20 and 24 whereas, a synonymous variation in exon 13, a missense variation in exon 16, and three missense mutation were detected in exon 11. Although 185delAG and 5382insC mutations in exon 2 and 20 of **BRCA1** gene respectively are known as founder mutations which are frequently observed in Ashkenazi Jewish breast cancer patients, in the current study, there were neither new nor reported mutations in these exons (11). Numerous studies have reported these polymorphisms in other populations (12, 13). Our findings are in line with the previous report from the other parts of Iran. Fattahi et al. investigated the frequency of 185delAG and 5382insC mutations in 55 women with a family histo-

http://miji.iums.ac.ir
ry of BC and 250 sporadic patients in the south of Iran by a multiplex PCR technique; their results revealed that the above-mentioned mutations were not detected in their cases (14). Bar-Sade et al. performed a study on a group consists of 150 Iranian Jews, 354 of Moroccan origin, and 200 Yemenites to detect the prevalence of \( \text{BRCA1} \) founder mutation (185delAG). Four of Moroccan origin (about 1.1%) and none of the Yemenites or Iranians have this mutation (15). However, some studies reported a low frequency of the 185delAG and 5382insC founder mutation in the \( \text{BRCA1} \) gene in Iranian breast cancer patients (16-19). Accordingly, it seems that the incidence of \( \text{BRCA1} \) founder mutations is rare among Iranian breast cancer.

In exon 13, a synonymous polymorphism (c. 4308T>C) was found in 36% of patients with familial breast cancer, and 32% of non-familial patients. This variant was documented in the 1000 Genomes project with a Reference SNP ID (rs1060915), and its frequency in Exome Sequencing Project (GO-ESP) was reported 27%. The majority of studies found this mutation as a polymorphism with low frequencies (20-22). Ghaderi et al. have studied 80 patients in the central part of Iran, Fars province. They reported that the prevalence of polymorphism (c. 4308T>C) was reported 36.4%, 50%, and 13.6% respectively for wild, heterozygous, and homozygous genotype (23). See et al. evaluated \( \text{BRCA1} \) mutations in 97 Korean patients with sporadic breast cancer and the polymorphism c. 4308T>C was observed in 30% of patients (24). Mundhofir et al. noted that the frequency of the heterozygous genotype of c. 4308T>C was 53.3% in Indonesian population (25).

Polymorphism (c. 4837A>G) in exon 16, which changes serine to glycine, was observed in 50 patients (7 of them were women with family history, and 43 were sporadic). Reference SNP ID of c. 4837A>G was recorded as rs1799966 with the frequency of 29% in GO-ESP. Keshavarzi et al. investigated entire coding sequences and all intron/exon of \( \text{BRCA1} \) genes in 85 patients. They reported this mutation as a polymorphism with a frequency of 21% (20). Also, Ghaderi et al. reported the prevalence of this mutation 50% and 13% for GG and AG genotypes respectively (23). Zhu et al. observed that rs1799966 (\( \text{BRCA1} \)) was significantly associated with pancreatic cancer \( p=0.0010 \), and this mutation can mostly be regarded as a risk biomarker of pancreatic cancer through (26).

Three missense polymorphism (c.3113A>G, c.3119G>A, c.3548A>G) were detected in exon 11. The frequency rate for c.3113A>G was 32.5%, for c.3119G>A was 5%, and the highest frequency belonged to c.3548A>G with 72.4% in familial breast cancer and 45.4% in non-familial breast cancer. The middle part of the protein encoded by exon-11 and more than half of the mutations occur in this exon (27). These variations (c.3113A>G, c.3119G>A, c.3548A>G) are known as rs16941, rs4986852 and rs16942 in NCBI and their frequencies were reported 27%, 1% and 29% in the database GO-ESP, respectively. These mutations have been reported in previous studies (20, 23). Pietschmann et al. screened complete coding sequences and 3’ and 5’ UTR regions of \( \text{BRCA1} \) in Iranian population. The polymorphism c.3113A>G, c.3119G>A and c.3548A>G were respectively identified in 30%, 10% and 30% of patients (21). Zanella et al. analyzed \( \text{BRCA1} \) and \( \text{BRCA2} \) genes by Ion AmpliSeq panel, a type of next-generation sequencing (NGS), in Italian patients. The frequency of variations c.3113A>G, c.3119G>A, c.3548A>G were 53%, 10%, and 53% separately (28).

There is a hypothesis that one of the functions of the \( \text{BRCA1} \) gene is regulation stem cells in breast tissue, in \( \text{BRCA1} \) damaged cells this regulatory function fails and these cells lose their tight proliferative control. Many studies confirmed the correlation of \( \text{BRCA1} \) gene with some marker of breast cancer stem cell. For instance, Madjd et al. showed that among various markers, increasing the expression of aldehyde dehydrogenase 1 (ALDH1) is inversely correlated with decreasing \( \text{BRCA1} \) in breast tissue. Their research suggested that increasing the cells expressing ALDH1, because of knockdown of \( \text{BRCA1} \) in breast epithelial cells, can be considered as a breast cancer prevention (29).

**Conclusion**

Our study concluded that \( \text{BRCA1} \) mutations are less frequent in patients with breast cancer who live in the East of Iran. Our results have confirmed previous evidence demonstrated that \( \text{BRCA1} \) mutations are less common between Iranian patients. Therefore, extensive studies are needed to identify founder mutation to provide appropriate cancer prevention, screening, and counseling strategies based on the mutation data for the Iranian population.

**Acknowledgments**

This study was financially supported by the Birjand University of Medical Sciences, Iran. (Grant No, 1145). We thank all colleagues and participants in this research.

**Conflict of Interests**

The authors declare that they have no competing interests.

**References**


http://mjiri.iums.ac.ir

Med J Islam Repub Iran. 2019 (2 Oct); 33.105.


http://mjiri.iums.ac.ir